VRNA vs. ELAN, KRYS, OGN, BBIO, APLS, RNA, CRNX, IMVT, ACLX, and XENE
Should you be buying Verona Pharma stock or one of its competitors? The main competitors of Verona Pharma include Elanco Animal Health (ELAN), Krystal Biotech (KRYS), Organon & Co. (OGN), BridgeBio Pharma (BBIO), Apellis Pharmaceuticals (APLS), Avidity Biosciences (RNA), Crinetics Pharmaceuticals (CRNX), Immunovant (IMVT), Arcellx (ACLX), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical products" industry.
Elanco Animal Health (NYSE:ELAN) and Verona Pharma (NASDAQ:VRNA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk, institutional ownership and community ranking.
97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 85.9% of Verona Pharma shares are owned by institutional investors. 0.6% of Elanco Animal Health shares are owned by company insiders. Comparatively, 4.8% of Verona Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Elanco Animal Health had 9 more articles in the media than Verona Pharma. MarketBeat recorded 15 mentions for Elanco Animal Health and 6 mentions for Verona Pharma. Elanco Animal Health's average media sentiment score of 0.57 beat Verona Pharma's score of 0.30 indicating that Verona Pharma is being referred to more favorably in the news media.
Elanco Animal Health has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, Verona Pharma has a beta of 0.44, meaning that its stock price is 56% less volatile than the S&P 500.
Elanco Animal Health presently has a consensus target price of $17.57, suggesting a potential upside of 36.32%. Verona Pharma has a consensus target price of $36.00, suggesting a potential upside of 58.38%. Given Elanco Animal Health's stronger consensus rating and higher possible upside, analysts clearly believe Verona Pharma is more favorable than Elanco Animal Health.
Verona Pharma has a net margin of 0.00% compared to Verona Pharma's net margin of -29.83%. Verona Pharma's return on equity of 5.98% beat Elanco Animal Health's return on equity.
Verona Pharma received 183 more outperform votes than Elanco Animal Health when rated by MarketBeat users. Likewise, 80.15% of users gave Verona Pharma an outperform vote while only 54.10% of users gave Elanco Animal Health an outperform vote.
Verona Pharma has lower revenue, but higher earnings than Elanco Animal Health. Verona Pharma is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.
Summary
Verona Pharma beats Elanco Animal Health on 10 of the 17 factors compared between the two stocks.
Get Verona Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VRNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Verona Pharma Competitors List
Related Companies and Tools
Free VRNA Stock Alerts